Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial-Reference-Cited by-同舟云学术

Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial

Published:2022-01-31 Issue:2 Volume:28 Page:392-400
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Miller Jeffrey S.^ORCID,Davis Zachary B.,Helgeson Erika,Reilly Cavan,Thorkelson Ann,Anderson Jodi,Lima Noemia S.^ORCID,Jorstad Siri,Hart Geoffrey T.,Lee John H.,Safrit Jeffrey T.,Wong Hing,Cooley Sarah,Gharu Lavina,Chung Hyunsoo^ORCID,Soon-Shiong Patrick^ORCID,Dobrowolski Curtis,Fletcher Courtney V.^ORCID,Karn Jonathan,Douek Daniel C.,Schacker Timothy W.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-021-01651-9.pdf

Reference32 articles.

1. Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512–517 (1999).

2. Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179–183 (2014).

3. Wagner, T. A. et al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570–573 (2014).

4. Estes, J. D. et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat. Med. 23, 1271–1276 (2017).

5. Fletcher, C. V. et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl Acad. Sci. USA 111, 2307–2312 (2014).

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 latency reversal and immune enhancing activity of IL-15 is not influenced by sex hormones;JCI Insight;2024-09-10

2. Advancing Toward a Human Immunodeficiency Virus Cure;Infectious Disease Clinics of North America;2024-09

3. Nogapendekin alfa Inbakicept: First Approval;Drugs;2024-07

4. Utilizing immunotherapy towards achieving a functional cure for HIV-1;Current Opinion in HIV and AIDS;2024-04-11

5. Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance;Medical Science Monitor;2024-04-01